Secondary analysis of CASSIOPEIA: in 195 patients with newly diagnosed multiple myeloma, baseline FDG-PET medullary total metabolic tumour volume independently predicted progression-free and overall survival (both P<.001), complementary to R-ISS.
Secondary analysisn = 195
Jamet et al. FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial